Clinical Trials › NCT06847724
RecruitingPhase 3
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Sponsored by Sandoz
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 175
Target enrollment
1
U.S. states
Jun 2025
Start date
Oct 2029
Expected completion
Interventions / Treatments
CYB704Ocrevus-EUOcrevus-US
Conditions studied
Relapsing Multiple Sclerosis
Where this trial is running (2 sites)
Florida2 sites
Maitland · Ormond Beach
MS centers in Florida
Compare treatment centers near a trial site by center type, providers and trials.
View Florida centersMore Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.